Analytical Data
-
基因名
SLAMF7/CRACC/CD319
- Application
-
别名
CD319; CRACC; 19A; CS1; CD2-like receptor-activating cytotoxic cells; Membrane protein FOAP-12
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q9NQ25
-
表达区间
Ser23~Met226
-
分子量
28kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLAMF7, also known as CRACC or CD319, is an important member of the SLAM (Signaling Lymphocyte Activation Molecule) family, primarily expressed on immune cells such as natural killer (NK) cells and certain T cells. This protein plays a crucial role in modulating immune responses, influencing both activating and inhibitory signals within the immune system. Due to its involvement in tumor immunity and viral infections, SLAMF7 has garnered significant attention as a potential therapeutic target in cancer treatment, particularly for multiple myeloma where its expression is notably upregulated. Research has revealed that SLAMF7 engagement enhances NK cell cytotoxicity and cytokine production, while also promoting immune system activation. As a result, recombinant forms of SLAMF7 are being explored for their ability to serve as therapeutic agents or targets in immunotherapies, including monoclonal antibodies. Despite promising findings, a comprehensive understanding of its signaling pathways and functional roles in different immune contexts remains necessary to harness its full therapeutic potential effectively.
